HUTCHMED Highlights SANOVO Phase III Data for ORPATHYS® plus TAGRISSO® in First-Line EGFR-Mutated Lung Cancer Presented at ESMO Congress 2026

Q: What did HUTCHMED's SANOVO trial show for ORPATHYS plus TAGRISSO?

ORPATHYS plus TAGRISSO reduced the risk of disease progression or death by 44% versus TAGRISSO alone in the overall trial population. Median progression-free survival was 24.9 versus 13.8 months, with p<0.0001. Median overall survival, a secondary endpoint, was 44.5 versus 34.9 months.

Q: What is HUTCHMED's next regulatory step after SANOVO?

HUTCHMED plans to submit a supplemental New Drug Application in China for the combination in the first-line setting. ORPATHYS plus TAGRISSO is already approved in China for locally advanced or metastatic EGFR mutation-positive non-squamous lung cancer with MET amplification after progression on EGFR-targeted therapy.

Q: How was HUTCHMED's SANOVO Phase III trial designed?

SANOVO was a blinded, randomized, controlled trial in China, assigning patients in a 1:1 ratio to TAGRISSO with either ORPATHYS or placebo. The primary endpoint was investigator-assessed progression-free survival. Eligible patients had an EGFR exon 19 deletion or L858R mutation and MET overexpression.

HUTCHMED plans a China application to extend the combination into first-line treatment following the SANOVO results.

Rhea-AI Impact

(Neutral)

Rhea-AI Sentiment

(Very Positive)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Rhea-AI Summary

HUTCHMED (HCM) reported Phase III SANOVO results showing ORPATHYS plus TAGRISSO reduced progression or death risk by 44% versus TAGRISSO alone.

The China trial enrolled 326 previously untreated patients with EGFR-mutated, locally advanced or metastatic non-small cell lung cancer and MET overexpression. Median progression-free survival, the time before disease worsens or death, was 24.9 versus 13.8 months overall. In the high-MET group, it was 24.8 versus 11.1 months, with a 55% risk reduction. Both comparisons were statistically significant. Median overall survival, a secondary endpoint, was 44.5 versus 34.9 months overall.

Adverse events caused treatment discontinuation in 14.8% of combination recipients; fatal adverse events excluding disease progression were 4.3% versus 4.8%. HUTCHMED reported no new safety concerns and plans a supplemental New Drug Application in China for first-line use.

6 points · 1 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance works How Sentiment works

0 major · 2 points

Hollow bars mark forward-looking points. How the balance works

Positive

Major pointOverall median progression-free survival reached 24.9 versus 13.8 months; progression or death risk fell 44% versus TAGRISSO alone.
Moderate pointMedian overall survival reached 44.5 versus 34.9 months; hazard ratio was 0.48.
Moderate point. Forward-looking: it has not happened yet and may not happen.HUTCHMED plans a supplemental New Drug Application in China for first-line treatment.
Minor pointHigh-MET median progression-free survival reached 24.8 versus 11.1 months; progression or death risk fell 55%.
Minor pointEstimated three-year survival was 67.4% versus 47.4% with TAGRISSO alone.
Minor pointHUTCHMED reported no new safety concerns with the combination.

Negative

Minor pointAdverse events caused treatment discontinuation in 14.8% of combination recipients.
Minor pointFatal adverse events excluding disease progression occurred in 4.3% versus 4.8% of patients.

Key Figures

PFS risk reduction: 44% PFS risk reduction: 55% Median PFS: 24.9 vs. 13.8 months +5 more

PFS risk reduction: 44%; ITT population vs. TAGRISSO® alone
PFS risk reduction: 55%; High MET population vs. TAGRISSO® alone
Median PFS: 24.9 vs. 13.8 months; ITT population; ORPATHYS® plus TAGRISSO® vs. comparator
Median PFS: 24.8 vs. 11.1 months; High MET population; ORPATHYS® plus TAGRISSO® vs. comparator
Median OS: 44.5 vs. 34.9 months; ITT population; ORPATHYS® plus TAGRISSO® vs. comparator
OS hazard ratio: 0.48 (95% CI 0.33–0.68); ITT population vs. TAGRISSO® alone
Alive at three years: 67.4% vs. 47.4%; ORPATHYS® plus TAGRISSO® vs. comparator
Treatment discontinuation due to adverse events: 14.8%; Patients receiving ORPATHYS® plus TAGRISSO®

Previous Clinical trial Reports

1 past event · Latest: Sep 23

Same Type 1 event

Sep 23
Clinical results

24h Move

-3.3%

Earlier high-level SANOVO findings established PFS and OS benefit versus osimertinib alone before detailed results.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

progression-free survival, hazard ratio, confidence interval, intention-to-treat, +1 more

5 terms

progression-free survival medical

"improvement in the primary endpoint progression-free survival"

Progression-free survival is the length of time during and after a treatment that a patient's disease does not get worse, measured from the start of treatment until the disease shows measurable signs of progression or the patient dies. Investors care because longer progression-free survival in clinical trials often signals that a drug is effective, improving chances of regulatory approval, market adoption, and revenue potential—think of it as a stopwatch showing how long a therapy can keep the illness at bay.

hazard ratio medical

"based on a PFS hazard ratio"

A hazard ratio is a way scientists compare the chance of something happening over time between two groups, like patients taking different medicines. If the ratio is high, it means one group is more likely to experience the event sooner or more often, which helps determine how effective a treatment is or how risky a situation might be.

confidence interval medical

"95% confidence interval"

An interval estimate that shows a range of values within which a true number (like a company’s expected earnings, a projected return, or a model input) is likely to lie, together with a stated level of confidence in that range. For investors it turns a single point forecast into a band—like a weather forecast saying 60–70°F instead of just 65°F—making uncertainty explicit so you can judge risk and size positions more sensibly.

intention-to-treat medical

"the intention-to-treat (“ITT”) trial populations"

A method for analyzing clinical trial results that counts every participant in the group they were originally assigned to, regardless of whether they completed the treatment or followed the protocol. Like judging a sports team's season based on the original roster rather than only the players who actually played every game, it gives a conservative, real-world estimate of how a treatment performs and helps investors judge the likelihood regulators and markets will value the therapy.

tyrosine kinase inhibitor medical

"an oral, potent and highly selective MET TKI"

A tyrosine kinase inhibitor is a type of drug that blocks specific proteins in cells that act like on/off switches for growth and survival signals, often used to stop cancer cells from multiplying. For investors, these drugs matter because their clinical trial results, regulatory approvals, safety profiles, and patent status drive sales potential and company valuation—think of them as precision tools whose effectiveness and market exclusivity determine commercial success.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

10/26/2026 - 04:30 AM EDT

— ORPATHYS^® plus TAGRISSO^® reduced the risk of disease progression or death by 44% in the overall population and 55% in the high MET overexpression population in the first-line setting —

— Robust PFS gains alongside very encouraging OS clinical benefit in this treatment-naïve biomarker-selected patient population —

— Offers a potential new standard of care through an all-oral, biomarker-driven frontline strategy for MET-overexpressing, EGFR-mutated lung cancer patients —

HONG KONG, SHANGHAI and FLORHAM PARK, N.J., Oct. 26, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces positive results from the SANOVO Phase III trial in China. ORPATHYS^® (savolitinib) plus TAGRISSO^® (osimertinib) demonstrated a statistically significant and highly clinically meaningful improvement in the primary endpoint progression-free survival (“PFS”) versus TAGRISSO^® alone in treatment-naïve patients with epidermal growth factor receptor-mutated (“EGFRm”) locally advanced or metastatic non-small cell lung cancer (“NSCLC”) and MET overexpression. The combination also demonstrated very encouraging clinical benefit in overall survival (“OS”), a secondary endpoint of the trial.

These results have been presented in a Proffered Paper session at the 2026 European Society for Medical Oncology (“ESMO”) Congress in Madrid, Spain (abstract #LBA69). ¹

PFS benefits were demonstrated in both the high MET (IHC 3+) and the intention-to-treat (“ITT”) trial populations (IHC 2+, IHC 3+). ORPATHYS^® plus TAGRISSO^® reduced the risk of disease progression or death by 44% compared to TAGRISSO^® alone in the ITT population (based on a PFS hazard ratio [“HR”] of 0.56; 95% confidence interval [“CI”] 0.43-0.74; p<0.0001). The combination demonstrated a median PFS of more than two years (24.9 months) compared to approximately a year (13.8 months) for TAGRISSO^® alone.

In the high MET population, ORPATHYS^® plus TAGRISSO^® reduced the risk of disease progression or death by 55% compared to TAGRISSO^® alone (PFS HR of 0.45; 95% CI 0.31-0.66; p<0.0001). ORPATHYS^® plus TAGRISSO^® extended median PFS by 13.7 months versus the comparator arm (24.8 versus 11.1 months).

For the secondary endpoint of OS in the ITT population, ORPATHYS^® plus TAGRISSO^® showed a clinically meaningful improvement in OS (OS HR of 0.48; 95% CI 0.33-0.68) versus TAGRISSO^® alone. ORPATHYS^® plus TAGRISSO^® extended median OS by 9.6 months versus the comparator arm (44.5 versus 34.9 months). An estimated 67.4% of patients treated with the combination were alive at three years compared to 47.4% in the comparator arm. With longer follow-up, the OS curves showed continued separation, signaling a greater magnitude of benefit over time for the ORPATHYS^® plus TAGRISSO^® combination. Importantly, the PFS and OS benefit observed was consistent across all prespecified ITT subgroups.

Professor Yi-Long Wu of the Guangdong Provincial People's Hospital, and the leading principal investigator of the trial, said: “The SANOVO results mark a pivotal evolution in how we approach first-line EGFR-mutated lung cancer. Historically, co-occurring MET alterations have been associated with poor outcomes on EGFR-TKI treatment, increasing the motivation to test for MET alterations at diagnosis and upon progression. These potentially practice-changing results showed that adding savolitinib to osimertinib extended median PFS by more than a year in the high MET population, and 11 months overall, in first-line MET-overexpressing EGFR-mutated lung cancer. Coupled with highly encouraging clinical benefit in OS, these data reinforce the transformative potential of this all-oral, biomarker-directed treatment approach for a patient population where co-occurring MET overexpression may limit the long-term benefits of EGFR-TKI monotherapy.”

Mr Johnny Cheng, Acting Chief Executive Officer and Chief Financial Officer of HUTCHMED, said: “SANOVO, alongside the SAFFRON and SACHI studies, establishes a comprehensive treatment continuum for the ORPATHYS^® plus TAGRISSO^® combination — spanning frontline intervention to post-EGFR-TKI resistance. SANOVO demonstrates that by identifying MET overexpression at diagnosis and initiating an all-oral, dual-targeted combination upfront, we can meaningfully extend PFS and OS while preserving patient quality of life. SANOVO reinforces our strategy to improve long-term clinical outcomes for patients by advancing precision oncology into earlier lines of therapy.”

Dr Jing He, Senior Vice President and Head of R&D China of AstraZeneca, said: “The SANOVO results build on the proven efficacy seen in SAFFRON and SACHI, bringing the benefit of ORPATHYS^® plus backbone TAGRISSO^® to first-line patients with EGFR-mutated lung cancer with co-occurring MET overexpression. By targeting both EGFR and MET pathways, this all-oral, biomarker-directed combination improved both progression-free and overall survival in this setting. These results allow us to further advance our strategy to redefine standards of care for patients with EGFR-mutated lung cancer by delivering novel, targeted combinations.”

Summary of PFS and OS results: SANOVO ⁱ

	ORPATHYS^® + TAGRISSO^® (n=162)	Placebo + TAGRISSO^® (n=164)
PFS (ITT) ⁱⁱ
Number of patients with event, n (%)	101 (62.3)	124 (75.6)
Median PFS (95% CI) (in months)	24.9 (22.1-27.6)	13.8 (10.9-16.6)
HR (95% CI)	0.56 (0.43-0.74)
p-value	p<0.0001
PFS (IHC3+>90%)
Number of patients, n	98	98
Median PFS (95% CI) (in months)	24.8 (19.4-27.6)	11.1 (8.3-16.6)
HR (95% CI)	0.45 (0.31-0.66)
p-value	p<0.0001
OS (ITT) ⁱⁱ
Number of deaths, n (%)	49 (30.2)	83 (50.6)
Median OS (95% CI) (in months)	44.5 (41.3-NE ⁱⁱⁱ)	34.9 (26.3-41.1)
HR (95% CI)	0.48 (0.33-0.68)
ⁱ PFS data cut-off was 31 July 2026. ⁱⁱ ITT = intention-to-treat (IHC 2+, IHC 3+) ⁱⁱⁱ NE = not estimable

The safety profile for ORPATHYS^® plus TAGRISSO^® was manageable and consistent with the known profiles of each medicine, and there were no new safety concerns. Demonstrating strong long-term tolerability, treatment discontinuation due to adverse events occurred in only 14.8% of patients receiving ORPATHYS^® plus TAGRISSO^®. Most adverse events were manageable with dose adjustments, and fatal adverse event rates (excluding disease progression) were low and balanced across treatment arms (4.3% versus 4.8%).

By simultaneously targeting EGFR and co-occurring MET pathway alterations at initial diagnosis, this chemotherapy-free, all-oral regimen intercepts bypass activation mechanisms before primary or early resistance emerges, offering robust clinical efficacy and sustained disease control while maintaining patient quality of life.

An additional presentation featured during a Presidential Symposium at the ESMO Congress highlighted data from the SAFFRON Phase III trial of ORPATHYS^® plus TAGRISSO^® in MET-driven EGFRm NSCLC after progression on TAGRISSO^® (abstract #LBA6). ²

ORPATHYS^® plus TAGRISSO^® is approved in China for patients with locally advanced or metastatic EGFRm-positive non-squamous NSCLC with MET amplification after disease progression on EGFR-tyrosine kinase inhibitor (“TKI”) therapy based on the SACHI Phase III trial. Based on data from the SANOVO Phase III trial, HUTCHMED plans to submit a supplemental New Drug Application in China for this first-line setting.

ORPATHYS^® is being jointly developed by AstraZeneca and HUTCHMED and commercialized by AstraZeneca.

About NSCLC and MET aberrations

Lung cancer is the leading cause of cancer death globally, accounting for almost one in four (23%) cancer deaths.³^,⁴ Lung cancer is broadly split into NSCLC and small cell lung cancer, with 80-85% of patients diagnosed with NSCLC.⁵ Approximately 75% of NSCLC patients are diagnosed with advanced disease.⁶ Additionally, about 10-15% of NSCLC patients in the US and Europe, and 30-40% of patients in Asia, have EGFRm NSCLC.⁷

MET is a tyrosine kinase receptor that has an essential role in normal cell development.⁸ MET overexpression or amplification can lead to tumor growth and the metastatic progression of cancer cells.⁸^,⁹

About SANOVO

SANOVO is a blinded, randomized, controlled Phase III trial in previously untreated patients with locally advanced or metastatic NSCLC with activating EGFR mutations and MET overexpression in China conducted by HUTCHMED. The study evaluates the efficacy and safety of ORPATHYS^® in combination with TAGRISSO^® compared to TAGRISSO^® alone, a standard-of-care treatment option for these patients. A total of 326 treatment-naïve patients with locally advanced or metastatic NSCLC harbouring EGFR mutations (exon 19 deletion or L858R) and MET overexpression were randomized in a 1:1 ratio to receive TAGRISSO^® 80 mg once daily plus either ORPATHYS^® or placebo at 300/200 mg twice daily (dosed based on body weight).

The primary endpoint of the trial is PFS as assessed by investigators. Other endpoints include PFS assessed by an independent review committee, OS, objective response rate, duration of response, disease control rate, time to response and safety.

About ORPATHYS^®

ORPATHYS^® (savolitinib) is an oral, potent and highly selective MET TKI that has demonstrated clinical activity in advanced solid tumors. It blocks atypical activation of the MET receptor tyrosine kinase pathway that occurs because of mutations (such as exon 14 skipping alterations or other point mutations), gene amplification or protein overexpression.

ORPATHYS^® is approved in China for the treatment of adult patients with locally advanced or metastatic NSCLC with MET exon 14 skipping alteration, representing the first selective MET inhibitor approved in China. ORPATHYS^® also received a conditional approval in China for the treatment of adult patients with locally advanced or metastatic gastric cancer or gastroesophageal junction (GC/GEJ) adenocarcinoma patients with MET amplification who have failed at least two prior systemic treatments. ORPATHYS^® in combination with TAGRISSO^® is approved in China for patients with locally advanced or metastatic EGFR mutation-positive non-squamous NSCLC with MET amplification after disease progression on EGFR-TKI therapy based on the SACHI Phase III trial. The combination was also granted a temporary authorization in Switzerland for the treatment of patients with locally advanced or metastatic EGFRm NSCLC and high levels of MET overexpression or amplification who progressed on prior treatment with TAGRISSO^®. This was based on results from the global SAVANNAH Phase II trial. The global, randomized, SAFFRON Phase III trial in the same treatment setting comparing the combination with doublet platinum-based chemotherapy reported positive high-level results, demonstrating a statistically significant and clinically meaningful improvement in PFS and OS in August 2026.

About TAGRISSO^®

TAGRISSO^® (osimertinib) is a third-generation, irreversible EGFR-TKI with proven clinical activity in NSCLC, including the treatment of central nervous system metastases.

TAGRISSO^® is approved as monotherapy in more than 120 countries including the US, EU, China and Japan. Approved indications include for first-line treatment of patients with locally advanced or metastatic EGFRm NSCLC, locally advanced or metastatic EGFR T790M mutation-positive NSCLC, adjuvant treatment of early-stage EGFRm NSCLC and locally advanced, unresectable NSCLC following platinum-based chemoradiation therapy. TAGRISSO^® is also approved in combination with chemotherapy in more than 80 countries, including the US, EU, China and Japan, for first-line treatment of patients with locally advanced or metastatic EGFRm NSCLC.

About HUTCHMED

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first four medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect HUTCHMED’s current expectations regarding future events, including its expectations regarding the therapeutic potential of ORPATHYS^®, the further clinical development for ORPATHYS^®, its expectations as to whether any studies on ORPATHYS^® would meet their primary or secondary endpoints, and its expectations as to the timing of the completion and the release of results from such studies. Forward-looking statements involve risks and uncertainties. Such risks and uncertainties include, among other things, assumptions regarding enrollment rates and the timing and availability of subjects meeting a study’s inclusion and exclusion criteria; changes to clinical protocols or regulatory requirements; unexpected adverse events or safety issues; the ability of ORPATHYS^®, including as a combination therapy, to meet the primary or secondary endpoint of a study, to obtain regulatory approval in different jurisdictions and to gain commercial acceptance after obtaining regulatory approval; the potential market of ORPATHYS^® for a targeted indication; the sufficiency of funding; HUTCHMED’s and AstraZeneca’s ability to successfully develop and commercialize ORPATHYS^®. In addition, as certain studies rely on the use of other drug products such as TAGRISSO^®as combination therapeutics with ORPATHYS^®, such risks and uncertainties include assumptions regarding the safety, efficacy, supply and continued regulatory approval of these therapeutics. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMED’s filings with the US Securities and Exchange Commission, The Stock Exchange of Hong Kong Limited and on AIM. HUTCHMED undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

Medical Information

This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

CONTACTS

Investor Enquiries	+852 2121 8200 /ir@hutch-med.com

Media Enquiries
FTI Consulting –	+44 20 3727 1030 /HUTCHMED@fticonsulting.com
Ben Atwell / Tim Stamper	+44 7771 913 902 (Mobile) / +44 7779 436 698 (Mobile)
Brunswick – Zhou Yi	+852 9783 6894 (Mobile) /HUTCHMED@brunswickgroup.com

Panmure Liberum	Nominated Advisor and Joint Broker
Atholl Tweedie / Emma Earl / Rupert Dearden	+44 20 7886 2500

Cavendish	Joint Broker
Geoff Nash / Nigel Birks	+44 20 7220 0500

Deutsche Numis	Joint Broker
Duncan Monteith / Ramin Naji	+44 20 7545 8000

^{________________________________________________}

REFERENCES
¹	Wu YL, et al. Savolitinib or Placebo Combined with Osimertinib in Treatment-Naïve Advanced NSCLC with EGFR Mutation and MET Overexpression: Results from the Phase 3 SANOVO Study. Presented at the European Society for Medical Oncology Congress 2026, 26 October at 08:30 CET.
²	Lu S, et al. Osimertinib [osi] + savolitinib [savo] vs platinum–pemetrexed [plat–pem] in EGFRm MET-overexpressed [OE] and/or -amplified [AMP] advanced NSCLC post-osi: SAFFRON Phase [Ph] 3 primary results. Presented in a Proffered Paper session during Presidential Symposium II the European Society for Medical Oncology Congress 2026, 25 October at 16:45 CET.
³	World Health Organization. International Agency for Research on Cancer. Lung Fact Sheet. Available at: https://gco.iarc.who.int/media/globocan/factsheets/cancers/15-trachea-bronchus-and-lung-fact-sheet.pdf. Accessed October 2026.
⁴	World Health Organization. International Agency for Research on Cancer. All Cancers Fact Sheet. Available at: https://gco.iarc.who.int/media/globocan/factsheets/cancers/39-all-cancers-fact-sheet.pdf. Accessed October 2026.
⁵	American Cancer Society. What Is Lung Cancer? Available at: https://www.cancer.org/cancer/types/lung-cancer/about/what-is.html. Accessed August 2026.
⁶	Chen HJ, et al. Long-term survival of advanced lung adenocarcinoma by maintenance chemotherapy followed by EGFR-TKI. Medicine. 2021;100(6):e24688.
⁷	Gao X, et al. The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer. Expert Rev Anticancer Ther. 2016;16(4):383-390.
⁸	Uchikawa E, et al. Structural basis of the activation of c-MET receptor. Nat Commun. 2021;12(4074)
⁹	Wang Q, et al. MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer. J Hematol Oncol. 2019;63.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did HUTCHMED's SANOVO trial show for ORPATHYS plus TAGRISSO?

ORPATHYS plus TAGRISSO reduced the risk of disease progression or death by 44% versus TAGRISSO alone in the overall trial population. Median progression-free survival was 24.9 versus 13.8 months, with p<0.0001. Median overall survival, a secondary endpoint, was 44.5 versus 34.9 months.

What is HUTCHMED's next regulatory step after SANOVO?

HUTCHMED plans to submit a supplemental New Drug Application in China for the combination in the first-line setting. ORPATHYS plus TAGRISSO is already approved in China for locally advanced or metastatic EGFR mutation-positive non-squamous lung cancer with MET amplification after progression on EGFR-targeted therapy.

How was HUTCHMED's SANOVO Phase III trial designed?

SANOVO was a blinded, randomized, controlled trial in China, assigning patients in a 1:1 ratio to TAGRISSO with either ORPATHYS or placebo. The primary endpoint was investigator-assessed progression-free survival. Eligible patients had an EGFR exon 19 deletion or L858R mutation and MET overexpression.

HUTCHMED Highlights SANOVO Phase III Data for ORPATHYS® plus TAGRISSO® in First-Line EGFR-Mutated Lung Cancer Presented at ESMO Congress 2026